Generation of specific monoclonal antibodies against the extracellular loops of human claudin-3 by immunizing mice with target-expressing cells
暂无分享,去创建一个
H. Misaka | K. Nakamura | H. Ando | N. Kimoto | A. Furuya | Mariko Kato-Nakano | Masayo Suzuki | S. Kawamoto
[1] K. Yagi,et al. Development of an Anti–Claudin-3 and -4 Bispecific Monoclonal Antibody for Cancer Diagnosis and Therapy , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[2] J. Viola,et al. Claudin-3 Overexpression Increases the Malignant Potential of Colorectal Cancer Cells: Roles of ERK1/2 and PI3K-Akt as Modulators of EGFR signaling , 2013, PloS one.
[3] M. J. Kwon,et al. Emerging Roles of Claudins in Human Cancer , 2013, International journal of molecular sciences.
[4] A. Santin,et al. Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy , 2013, International journal of molecular sciences.
[5] A. Yu,et al. Claudins and the modulation of tight junction permeability. , 2013, Physiological reviews.
[6] S. Howell,et al. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. , 2012, Neoplasia.
[7] T. Tomita,et al. Down-Regulation of Claudin-3 Is Associated with Proliferative Potential in Early Gastric Cancers , 2012, Digestive Diseases and Sciences.
[8] K. Nakamura,et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. , 2010, Anticancer research.
[9] Anton Hagenbeek,et al. CD20-targeted therapy: the next generation of antibodies. , 2010, Seminars in hematology.
[10] M. Cragg,et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. , 2010, Seminars in hematology.
[11] H. Misaka,et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin‐4 for pancreatic and ovarian cancers , 2009, Cancer science.
[12] A. Santin,et al. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. , 2009, American journal of obstetrics and gynecology.
[13] M. Sairam,et al. Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants. , 2006, Neoplasia.
[14] M. Brännström,et al. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours , 2006, International journal of cancer.
[15] P. Kufer,et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy , 2005, Cancer Immunology, Immunotherapy.
[16] P. Parren,et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.
[17] K. Shitara,et al. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. , 2000, Molecular immunology.
[18] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.